Marcus Kelly

Marcus Kelly

Company: Regeneron Pharmaceuticals

Job title: Associate Director - Oncology & Angiogenesis


Preclinical And Clinical Immuno-PET to Empower Development Of Antibody Therapeutics 2:45 pm

Overview of immuno-PET probes and considerations common with targeted radionuclide therapies Demonstrate the value of preclinical immuno-PET in the development of antibody-based therapeutics including T-cell engaging bispecifics and ADCs Illustrate the challenges and opportunities in the clinical application of immuno-PET agents in diagnostic/ prediction of response applications for cancer immunotherapiesRead more

day: Track A

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.